<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: The assessment of the value of the antibody QBEND10, which is directed against the haemopoietic stem cell related antigen CD34, in the immunohistochemical diagnosis of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> in routinely processed bone marrow biopsy specimens </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: 581 formalin fixed, paraffin embedded trephine biopsy specimens of the iliac crest were immunostained with QBEND10 (avidin-<z:chebi fb="1" ids="15956">biotin</z:chebi> complex/ABC method) </plain></SENT>
<SENT sid="2" pm="."><plain>The number of CD34+ haemopoietic stem cells/blast cells (referred to hereafter as CD34+ cells) was determined in each case </plain></SENT>
<SENT sid="3" pm="."><plain>The Wilcoxon test was used for statistical analysis </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The following diagnostic categories were defined: (1) <z:mpath ids='MPATH_458'>normal</z:mpath> or reactive bone marrow (n = 356), (2) <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo>, usually non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> of low grade <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> or <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> (n = 118), (3) <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (n = 22), (4) <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (n = 44), and (5) <z:mpath ids='MPATH_512'>myeloproliferative diseases</z:mpath> (n = 41) </plain></SENT>
<SENT sid="5" pm="."><plain>The average number of CD34+ cells was very low (0.2/HPF) in <z:mpath ids='MPATH_458'>normal</z:mpath> and reactive bone marrow, in <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> and in the <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> subtypes RA and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain><z:mpath ids='MPATH_512'>Myeloproliferative diseases</z:mpath> showed an average of three CD34+ cells/HPF </plain></SENT>
<SENT sid="7" pm="."><plain>However, the average number of CD34+ cells was significantly higher (p &lt; 0.05) in the <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> subtypes <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e> (8.7/HPF) and in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (including both myeloid and lymphoblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath>; 111.7/HPF) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: QBEND10 is of value for the identification of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e> in routinely processed bone marrow biopsy specimens because it enables the detection of even small increases in the number of CD34+ cells </plain></SENT>
</text></document>